Experimental virus therapy targets Hard-to-Treat cancers in early trial
NCT ID NCT06063317
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This early-phase study tested a new treatment called onCARlytics (CF33-CD19), a virus designed to infect and kill cancer cells, given alone or with the immune drug blinatumomab. The trial enrolled 25 adults with advanced solid tumors that had not responded to at least two prior therapies. The study was terminated early, but researchers collected safety data and looked for signs of immune response and tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Emory Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Northwestern
Chicago, Illinois, 60208, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
University of Cincinnati
Cincinnati, Ohio, 45219, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15219, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
onCARlytics (CF33-CD19) and blinatumomab
What this could lead to
If successful, this approach could point toward a new way to treat advanced solid tumors by using a virus to target cancer cells and an immune therapy to boost the attack.
What could go wrong
This was a very early (Phase 1) study that was terminated, so results are limited. The combination may cause significant side effects, and it is unclear if it will shrink tumors or improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.